Cat. #153423
H376 Cell Line
Cat. #: 153423
Unit size: 1x10^6 cells / vial
Availability: 10-12 weeks
Tissue: Oral Cavity
Disease: Cancer
Model: Tumour cell line
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Stephen Prime
Institute: University of Bristol
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: H376 Cell Line
- Alternate name: H-376; h-376
- Research fields: Cancer
- Tissue: Oral Cavity
- Disease: Cancer
- Growth properties: Adherent
- Model: Tumour cell line
- Conditional: Yes
- Description: H376 was established from a squamous cell carcinoma (SCC) of the floor of the mouth (20mm-40mm) of a 40 year-old female patient. In culture these cells scatter, i.e. the cells redistribute on the substrate, in response to Hepatocyte Growth Factor. H376 has the following features: STNMP stage III, well differentiated and a node positive tumour. This cell line has mutant p53, codon 266 exon 8, G to T; wild type K-, N-, and Ha-ras. H376 cells are non-tumourigenic in athymic nude mice by subcutaneous injection and on injection into the floor of the mouth (orthotopic). Haplotype information: A*03,A*24; B*27,B*35; Cw*04,Cw*12. Explore more human oral SCC cell lines from the same inventor including: H157, H357, H400, H314 and H103.
- Cellosaurus id: CVCL_2463
Target Details
- Target: Human oral squamous cell carcinoma, floor of mouth
Handling
- Format: Frozen
- Growth medium: Split sub-confluent cultures (70-80%), approximately every 5-6 days, 1:8 to 1:10 using 0.25% trypsin/EDTA; 5% CO2; 37°C. Suggested seeding density 5 x 1000 cells/cm2. DMEM:HAMS F12 (1:1) + 2mM Glutamine + 10% Foetal Bovine Serum (FBS) + 0.5 ug/ml sodium hydrocortisone succinate.
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
References
- Yeudall et al. 1995. Eur J Cancer B Oral Oncol. 31B(2):136-143. PMID: 7633286.
- Prime et al. 1994. Int J Cancer. 56(3):406-412. PMID: 7508893.
- Prime et al. 1994. Br J Cancer. 69(1):8-15. PMID: 8286215.
- Yeudall et al. 1993. Eur J Cancer B Oral Oncol. 29B(1):63-67. PMID: 8180579.
- Prime et al. 1990. J Pathol. 160(3):259-269. PMID: 1692339.
